Rossari Biotech’s MD Sunil Chari breaks down the company’s record-breaking Q2 Results　 #ETNOW

Revenue grew 18% year-on-year, EBITDA rose 9%, and exports surged 36%, now making up 28% of total sales — the highest ever.

However, global headwinds from the US and European markets, along with pricing pressure from China, impacted margins.
Rosari is now diversifying exports into MENA, Far East, and Southeast Asia, focusing on sustainable, balanced growth.

Chari also expects domestic demand to recover in the second half of the fiscal year as momentum builds across key verticals like home care, pharma, and agro.

Watch this exclusive ET Now interview to understand Rosari Biotech’s growth strategy, export plans, and margin outlook for FY26.

#rossaribiotech #sunilchari #q2results #exportgrowth #indianstocks #chemicalsector #etnow

control your money with economic times now.

YouTube Channel – https://www.youtube.com/@ETNow

Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow

Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb

Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC

Website – https://ift.tt/dyHSZ9g